Jintel Health, a technology innovator in advanced analytics and artificial intelligence, announced today that it will combine its Precision Intelligence solutions with Intermountain Healthcare’s Precision Medicine Program’s genomic and clinical data to analyze and distill the key insights that will enable Intermountain Oncologists to identify and predict the most effective therapies for their cancer patients.

Jintel Health and Intermountain Healthcare completed a Proof of Concept project in August of 2018 that aggregated clinical and genomic patient data from disparate sources, applied Jintel’s advanced analytics and artificial intelligence models, and generated insights and discoveries. The use of these insights leads to improved patient clinical outcomes and reduced costs of providing care.

“Jintel Health’s solutions improves Intermountain’s ability to meet its goal of providing true precision medicine by liberating key insights from its latent data sets to accelerate access to correct treatments, improve clinical outcomes, and reduce costs,” said Lincoln Nadauld, MD, executive director of Precision Genomics for Intermountain Healthcare.

“Jintel Health is proud to be working hand in hand with one of the world’s leading Precision Medicine Programs,” said Dr. Ping Zhang, CEO of Jintel Health.

About Jintel Health

Jintel Health has developed an innovative precision intelligence platform which captures and structures large clinical and genomic datasets, and then applies our advanced analytics and machine learning to enable precision medicine. Our team has extensive experience and success in leading Healthcare IT companies serving providers, payers and pharma’s. Our Precision Analytics and Precision Intelligence solutions have been successfully implemented at large Healthcare IDNs where the combined genomic, clinical and outcome data were analyzed using Jintel Artificial Intelligence tools to advance precision medicine and enable novel discoveries.